Great strides have been made in developing potent antiretroviral regimens
that block human immunodeficiency virus (HIV) transcription and assembly.
Despite these therapeutic advances, problems of drug resistance, latent viral
reservoirs, and drug-induced toxic effects that compromise effective viral
control point to the need for new classes of anti-HIV drugs with different
modes of action. One promising approach involves blocking HIV entry into human
cells, a complex process that involves multiple protein interactions. The
process of HIV entry begins with binding of the viral envelope glycoprotein
to both the CD4 receptor and one of several chemokine receptors and ends with
fusion of viral and cell membranes. Conceptually, there are 3 steps in the
HIV entry process that could serve as therapeutic targets: binding of the
viral envelope glycoprotein with the CD4 receptor, binding of the envelope-CD4
complex to chemokine receptors, and fusion of the viral and cell membranes.
Preclinical and clinical assessment of these entry inhibitors is ongoing and
will determine if they possess properties required for drug licensure. Moreover,
the worldwide epidemic is largely occurring in developing countries that cannot
afford these drugs: a prophylactic vaccine is necessary and urgent. New knowledge
of the HIV-envelope glycoprotein has also provided insight into possibilities
for the design of novel HIV vaccines.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 75
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.